tuneTypical Dose
Trials are sparse and formulation specific
Bee Product
Bee Pollen
Bee pollen
Evidence TierDWADA NOT PROHIBITED
watchEffect Window
Clinical evidence is too sparse for a dependable response window.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Bee pollen has very limited human evidence and a meaningful allergy risk, so it should not be treated as a general vitality or hormone-support supplement.
Bee pollen is sold for energy, immunity, menopause, and athletic recovery, but the evidence is thin. The best human study is a crossover trial in breast-cancer patients with menopausal symptoms, and even that study used a pollen-honey mixture against honey rather than a neutral placebo. That makes the efficacy signal hard to interpret, while the allergy risk remains real.
Bee pollen contains mixed plant and bee-derived compounds, but broad vitality claims are not supported by strong clinical evidence.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Very limited evidence for menopausal-symptom relief in a mixed pollen-honey formulation
Secondary Outcomes
- Strong allergy caution
Safety
Contraindications and Interactions
Contraindications
- Bee-product or pollen allergy
Side effects
- Allergic reaction
Interactions
No entries provided
Avoid if
- You have bee, pollen, or seasonal-allergy sensitivity
Evidence
Study-level References
bep-SRC-001Randomized crossover trial
Sourceopen_in_newWinther K, et al. Bee pollen and honey for the alleviation of hot flushes and other menopausal symptoms in breast cancer patients. Climacteric. 2015. doi:10.3109/13697137.2015.1065421. PMID:26171198.
Population: Breast-cancer patients receiving antihormonal treatment and experiencing menopausal symptoms.
Dose protocol: Pollen-honey mixture versus honey in crossover fashion
Key findings: Some menopausal symptom relief, but comparator choice weakens interpretation.
Notes: Best available human study, still low confidence.
Paper content
This is the main human bee-pollen trial. It suggests possible menopausal symptom relief, but interpretation is weakened because the comparator was honey instead of an inert placebo.
bep-SRC-002Multicenter, randomized, double-blind, placebo-controlled phase 3 trial
Sourceopen_in_newWagenlehner FME, Schneider H, Ludwig M, Schnitker J, Brahler E, Weidner W. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol. 2009;56(3):544-551. doi:10.1016/j.eururo.2009.05.046. PMID:19524353.
Population: Men with inflammatory chronic prostatitis or chronic pelvic pain syndrome (NIH category IIIA).
Dose protocol: Standardized pollen extract (Cernilton), two capsules every 8 hours for 12 weeks
Key findings: Significant improvement in pain, quality of life, and total symptom scores versus placebo in men with chronic prostatitis. 70.6% response rate versus 50.0% for placebo.
Notes: Uses a standardized pollen extract rather than raw bee pollen, so the result should not be generalized to all bee pollen products.
Paper content
This phase 3 multicenter RCT tested a standardized pollen extract (Cernilton) for 12 weeks in 139 men with inflammatory chronic prostatitis or chronic pelvic pain syndrome. The pollen extract group showed significantly greater improvement in pain, quality of life, and total NIH-CPSI scores compared with placebo, with a 70.6% response rate versus 50.0% for placebo. The treatment was well tolerated with minimal adverse effects.